Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update [Yahoo! Finance]
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
Tharimmune, Inc. (NASDAQ: THAR) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs [Yahoo! Finance]
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs